Exciting developments in microglia research in Alzheimer’s disease
Genetic studies have shown that the vast majority of risk genes for Alzheimer’s Disease (AD) are highly, or even preferentially,…
Date: 14th April 2023
Expert perspectives on lecanemab
On January 6, 2023, the US Food and Drug Administration (FDA) approved lecanemab for the treatment of Alzheimer’s disease (AD),…
Date: 15th March 2023
Exciting developments in microglia research in Alzheimer’s disease
Genetic studies have shown that the vast majority of risk genes for Alzheimer’s Disease (AD) are highly, or even preferentially,…
Date: 14th April 2023
Expert perspectives on lecanemab
On January 6, 2023, the US Food and Drug Administration (FDA) approved lecanemab for the treatment of Alzheimer’s disease (AD),…
Date: 15th March 2023
Nutrition and cognitive decline
Cognitive decline caused by dementia is one of the leading causes of disability and dependency for older adults globally, and…
Date: 5th December 2022
Novel markers for Alzheimer’s disease monitoring and prognostication
Our current podcast series is focused on Alzheimer’s disease biomarkers. Hundreds of studies have emerged in recent years that have…
Date: 31st October 2022
Early biomarkers for Alzheimer’s disease
Blood biomarkers are taking off in the Alzheimer’s disease field, showing promise for diagnosis, prognostication, and treatment monitoring. As more…
Date: 7th October 2022
Alzheimer’s disease blood tests? Bringing plasma biomarkers into clinical practice
Blood biomarkers are taking off in the Alzheimer’s disease field, showing promise for diagnosis, prognostication, and treatment monitoring. Current diagnostic…
Date: 6th September 2022
Immunotherapy for Alzheimer’s disease: targeting β-amyloid and tau
The complexity of Alzheimer’s disease (AD) pathogenesis has led to difficulties understanding the disease and, therefore, impacted the development of…
Date: 29th July 2022
Synaptic function in Alzheimer’s disease
Alzheimer’s disease (AD) is a neurodegenerative disorder predominately afflicting the older population – and with recent exponential developments in medicine…
Date: 15th June 2022
Novel developments in biomarkers for FTD
Frontotemporal dementia (FTD) occurs when nerve cells in the frontal and temporal lobes of the brain are lost, causing the…
Date: 7th April 2022
Therapeutic plasma exchange to slow cognitive decline in Alzheimer’s disease
Therapeutic plasma exchange (TPE) is used to treat a variety of neurological, immunological, and metabolic disorders. The procedure removes patient…
Date: 3rd February 2022
Recent advances in plasma biomarkers for Alzheimer’s disease
In recent years, blood-based biomarkers have taken off in the dementia space, representing a less invasive, more cost-effective, and accessible…
Date: 2nd February 2022
